Your prediction
Pros and Cons of Merrimack Pharmaceuticals Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Merrimack Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | -0.470% | 1.501% | 6.242% | -4.991% | 3.525% | 200.937% | -1.306% |
| Krystal Biotech | 5.350% | 6.399% | 17.592% | 14.742% | 32.194% | 183.380% | - |
| Evolus Inc | -1.720% | -2.521% | -4.132% | -50.847% | -44.762% | -12.782% | 90.164% |
Comments
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
